At least 250 million people worldwide are chronically infected with HBV, a small
hepatotropic DNA virus that replicates through reverse transcription. Chronic infection …

Current antiviral therapies, such as pegylated interferon-α and nucleos (t) ide analogues,
effectively improve the quality of life of patients with chronic hepatitis B. However, they can …

Background & Aims Several steps in the HBV life cycle remain obscure because of a lack of
robust in vitro infection models. These steps include particle entry, formation and …

Hepatitis B virus (HBV) infection remains a major public health concern worldwide with
about 257 million individuals chronically infected. Current therapies can effectively control …

Chronic hepatitis B virus (HBV) infection continues to be a major health burden worldwide; it
can cause various degrees of liver damage and is strongly associated with the development …

As obligate intracellular parasites, viruses need a host cell to provide a milieu favorable to
viral replication. Consequently, viruses often adopt mechanisms to subvert host cellular …

Hepadnaviruses, including human hepatitis B virus (HBV), replicate through reverse
transcription of an RNA intermediate, the pregenomic RNA (pgRNA). Despite this kinship to …

Background and Aims Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), a
mini-chromosome essential for HBV replication, is supposed to be resistant to nucleos (t) ide …

Objective The stability of the covalently closed circular DNA (cccDNA) in nuclei of non-
dividing hepatocytes represents a key determinant of HBV persistence. Contrarily, studies …

Chronic hepatitis B virus (HBV) infection remains a major health problem affecting
approximately 400 million people worldwide. Although HBV replication is only mildly …